Effects of Long-acting muscarinic antagonist(LAMA) and Long-acting beta-two-agonist (LABA) combination on dynamic pulmonary hyperinflatio

Phase 4

• Conditions: Chronic Obstructive Pulmonary Disease

• Registration Number: JPRN-UMIN000027521
• Lead Sponsor: Shinshu University Hospital,Department of Rehabilitation

Brief Summary

Five of the 38 registered patients dropped out of the study. The reasons for dropping out were hospitalization due to gastrointestinal disorder, discontinuation of hospital visits for unknown reasons, refusal to undergo examination after treatment, hospitalization due to exacerbation of respiratory diseases, and did not meet the criteria of COPD after registration into the study in one patient each. All results were not trough values. Because. Characteristics of patients and comparison of lung functions before and after treatment The study population included patients with mild to severe disease as determined by classification of airflow limitation severity using %FEV1, 60% of all subjects were moderate disease status. FEV1, %FEV1, and FEV1/FVC (forced vital capacity) ratio were significantly higher after in comparison to before treatment , while CAT was lower after treatment. Comparison of dynamic lung hyperinflation following metronome-paced incremental hyperventilation (MPIH) and 6MWT before and after treatment -IC20, -IC30, and -IC40 were significantly decreased after treatment. IC20, IC30, and IC40 increased significantly after treatment. In addition, deltaIC was significantly decreased after treatment. The 6MWD was significantly increased after treatment.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-05-31
• Study Completion: 2018-11-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 38

Inclusion Criteria

Not provided

Exclusion Criteria

Patients with dysuria due to prostate hypertrophy, glaucoma, severe heart failure, exacerbation and/or respiratory infection within 3 months, prior history of lung surgery, severe heart disease, or impairment or difficulty in walking due to motor or cognitive dysfunction were excluded. Exacerbation history criteria was defined as an acute worsening of respiratory symptoms that result in additional therapy.

Study & Design

• Study Type: Interventional
• Study Design: Not specified